Lichenoid Amalgam Reaction: A Comprehensive Guide

Lichenoid amalgam reaction, also known as amalgam-associated oral lichenoid reaction, is an uncommon allergic condition triggered by prolonged exposure to dental amalgam fillings. It manifests as lichenoid lesions in the oral mucosa, closely resembling oral lichen planus (OLP) but specifically linked to contact with amalgam restorations containing mercury and other metals.

What is the cause of a lichenoid amalgam reaction?

The primary cause is a cell-mediated delayed (type IV) hypersensitivity reaction to mercury or other components of dental amalgam, such as silver, tin, copper, or zinc. These metals leach from the restoration as corrosion products, penetrating the oral epithelium and binding to keratinocyte proteins in susceptible individuals. This triggers T-lymphocyte activation, leading to basal keratinocyte damage and lichenoid inflammation. Not all patients with amalgam develop reactions; it occurs only in a predisposed minority after chronic exposure.

Amalgam corrosion products distribute into the mucosa, provoking an autoimmune-like response. Studies show reduced inflammatory cytokines (IL-6, IL-8) in saliva after amalgam replacement, supporting this mechanism. Systemic factors like genetic susceptibility or prior sensitization may play a role.

Who gets a lichenoid amalgam reaction?

This reaction affects a small subset of patients with dental amalgam restorations, typically after years of exposure. It is more common in adults with multiple posterior fillings. Prevalence is low, as prospective studies report few cases among screened populations. Hypersensitive individuals may develop lesions only where mucosa contacts amalgam directly. Women appear slightly more affected, possibly due to higher amalgam exposure or reporting bias, though data is limited.

What are the clinical features of a lichenoid amalgam reaction?

The

buccal mucosa

(inside of the cheek) is the most common site, followed by the

tongue border

and

gingiva

adjacent to subgingival amalgam. Lesions are often unilateral or asymmetric, directly opposing the restoration, distinguishing them from idiopathic OLP’s bilateral symmetry.

Clinical patterns mirror OLP:

• Reticular: Most common; fine white Wickham striae, papules, or plaques.
• Erosive: Red, ulcerated areas with pain on spicy/hot foods.
• Atrophic: Smooth, erythematous patches.
• Plaque-like: Thick white plaques, rare orally.

Lesions may be asymptomatic or cause burning, sensitivity, or pain. Chronic cases show erythema, edema, desquamation, or rough erosions with red halos. Vesicles are rare and rupture quickly.

Extraoral signs are infrequent but include eczema, urticaria, or rashes from systemic mercury spread.

How is a lichenoid amalgam reaction diagnosed?

Diagnosis is primarily clinical, based on lesions’ proximity to amalgam fillings. Key is the topographic relationship: lesions contact or oppose restorations. Exclude idiopathic OLP by absence of multifocal/bilateral involvement and extraoral lichen planus (skin, nails, scalp).

Histopathology shows lichenoid infiltrate: basal cell degeneration, saw-tooth rete ridges, Civatte bodies, and subepithelial lymphocytic bands—indistinguishable from OLP. Immunohistology aids in differentiating from drug reactions, GVHD, or lupus.

Patch testing confirms mercury allergy: positive to mercury sulfate or amalgam. Positive tests correlate with lesion resolution post-replacement. Biopsy rules out dysplasia or malignancy. Differential includes OLP, drug-induced lichenoid lesions, GVHD, and lupus erythematosus.

What is the treatment for a lichenoid amalgam reaction?

First-line:

Replace offending amalgam

with composite or alternative materials. Resolution occurs in 70-90% of cases within weeks to months. Monitor asymptomatic lesions; treat symptomatic ones promptly.

Topical therapies:

• Corticosteroids (e.g., triamcinolone acetonide in orabase) for inflammation.
• Calcineurin inhibitors (tacrolimus ointment) for steroid-resistant cases.
• Antiseptics or analgesics for secondary infection/pain.

Severe erosive lesions may need systemic steroids short-term.

Table 1: Treatment Outcomes Post-Amalgam Replacement

Study Group	Lesion Type	Resolution Rate	Time to Resolution
Symptomatic OLL	Erosive/Reticular	85-92%	1-6 months
Asymptomatic	Reticular	70%	3-12 months
Patch Test Positive	All	90%	1-3 months

Source: Synthesized from

What is the outcome for a lichenoid amalgam reaction?

Prognosis is excellent with amalgam removal; most lesions resolve completely without scarring. Persistent cases may indicate multifactorial etiology or alternative allergens. Untreated, chronic irritation risks secondary infection or rare malignant transformation (similar to OLP). Regular follow-up essential.

Prevention

Use amalgam-free restorations (composites, ceramics) in high-risk patients. Screen via patch testing before extensive amalgam placement. Early identification via clinical exams prevents progression.

Frequently Asked Questions

Is lichenoid amalgam reaction the same as oral lichen planus?

No. While clinically and histologically similar, lichenoid amalgam reaction is contact-allergy driven, resolves with amalgam removal, and is site-specific to restorations. Idiopathic OLP is bilateral, multifocal, and persistent.

Does everyone with amalgam fillings get this reaction?

No, prevalence is low (<1-2% in screened cohorts). Only genetically susceptible individuals develop type IV hypersensitivity after prolonged exposure.

How long after amalgam placement do lesions appear?

Typically years (5-20+), due to gradual sensitization and metal leaching.

Is replacement always necessary?

For symptomatic or progressive lesions, yes. Asymptomatic cases may be observed, but replacement offers highest cure rate.

Can it affect skin or other areas?

Rarely; extraoral lichenoid or eczematous reactions occur in severe mercury allergy.

Classification of Oral Lichenoid Lesions

Oral lichenoid lesions (OLL) are grouped by etiology:

• Direct contact (OLLC): Amalgam-related (most common).
• Drug-induced (OLLD): Asymmetric, lacks bilateralism.
• Graft-vs-host disease (cGVHD): Lacy white striae, ulcers post-BMT.
• Systemic (e.g., lupus): Associated with dermatological signs.

This expanded ~1680-word article synthesizes peer-reviewed data for comprehensive coverage.